Peptide Therapeutics, Including GLP-1 Receptor Agonists

Advance your lead peptide candidates from discovery to market

Peptide therapeutics, encompassing a range of synthetic and recombinantly created peptides, including    GLP-1 recombinant analogs, represent a rapidly advancing frontier in pharmaceutical development for a range of conditions. Due to their structural complexity, susceptibility to degradation, and the presence of multiple possible contaminants like residual solvents and synthesis by-products, analyzing peptides can be challenging. Advanced analytical techniques such as mass spectrometry and high-performance liquid chromatography (HPLC) are essential for accurate analysis. Agilent supports your therapeutic peptide development with seamless characterization workflows, effortless integration, and expert guidance

Complete Your Journey to Therapeutic Success

End-to-end solutions and support to bridge every gap in your GLP-1 receptor agonists and peptide characterizations

Download our application compendium and Workflow resource guide.

    This is co-hosted by Express Pharma and Agilent

    By submitting this form, you are confirming you are an adult 18 years or older and agree to Express Pharma contacting you with marketing-related emails or by telephone. You may unsubscribe from receiving such communications from Express Pharma at any time. Express Pharma web sites and communications are subject to our Privacy Notice and Terms of Use.

    Yes, I would like to receive email updates about Agilent products, services and events.
    For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policy


    Comments (0)
    Add Comment